# Combined top 10 from each PICO category for PIIS0923753422047810_cleaned.json

## Population

1. (Patients, score 9) osed [IV, A].
nitions of high GCN vary and, in absence of current (cid:3) The molecular tests below are recommended in patients
standardisation, confound existing data. MET exon 14 with advanced non-squamous-cell carcinoma, and not
skipping mutations may be detected by DNA-based NGS, recommended in patients with a confident diagnosis of
but RNA-based NGS may also identify additional cases squamous-cell carcinoma, except in unusual cases, e.g.
missed by DNA sequencing.7 MET amplification is an young (<50 years) patients, never (<100 cigarettes in a
importantresistancemechanismdrivingacquiredresistance

2. (Patients, score 8) itu hybridisation (ISH) techniques, but NGS or compar- NSCLC-not otherwise specified rate to fewer than 10%
ative genomic hybridisation may also identify cases. Defi- of cases diagnosed [IV, A].
nitions of high GCN vary and, in absence of current (cid:3) The molecular tests below are recommended in patients
standardisation, confound existing data. MET exon 14 with advanced non-squamous-cell carcinoma, and not
skipping mutations may be detected by DNA-based NGS, recommended in patients with a confident diagnosis of
but RNA-based NGS may also identify additional cases squamous-cell carcinoma, except in

3. (Patients, score 8) cinoma, and not
skipping mutations may be detected by DNA-based NGS, recommended in patients with a confident diagnosis of
but RNA-based NGS may also identify additional cases squamous-cell carcinoma, except in unusual cases, e.g.
missed by DNA sequencing.7 MET amplification is an young (<50 years) patients, never (<100 cigarettes in a
importantresistancemechanismdrivingacquiredresistance lifetime)/former light smokers ((cid:4)15 pack-years, all kinds
to EGFR (including osimertinib) and ALK inhibitors. of tobacco) or long-time ex-smokers (quit smoking >15
Mesenchymal-epithelial transition (MET) kinase

## Intervention

1. (Therapy, score 5) appro-
Diagnostic procedures
priatedrugs.1Testingismandatoryforoncogenicdriversfor
whichdrugsareapprovedforroutineusage.Broadertesting
Details on diagnostic procedures are covered in the
maybeusedtosupportearlydrugaccessorclinicaltrials.2,3
SupplementaryMaterialSection2,availableat
For personalised therapy approaches, European Society for
10.1016/j.annonc.2022.12.009.SeeSupplementaryFigureS1,
Medical Oncology (ESMO) Scale for Clinical Actionability of
availableat
molecular Targets (ESCAT) classifications4 need to be
aflowchartondiagnosisandtestingbiopsy/cytologysamples
considered (Supplementary Table

2. (Treatment, score 3) ntificInstitute,Milan,Italy;15DepartmentofThoracic
Oncology,AirwayResearchCenterNorth,GermanCenterforLungResearch,LungClinic,Grosshansdorf,Germany
Availableonline23January2023
Keywords:ESCAT,ESMOClinicalPracticeGuideline(CPG),ESMO-MCBS,oncogene-addictedmetastaticnon-small-cell
lung cancer (mNSCLC), treatment, targeted therapy
INCIDENCE AND EPIDEMIOLOGY therapy.ThefrequencyofoncogenicdriversinNSCLCaswell
as general discussion of testing strategy and methodology,
Details on incidence and epidemiology are covered in the
including the use of liquid biopsies, can be found in the
Supplementary Material Secti

3. (Therapy, score 3) n,Italy;15DepartmentofThoracic
Oncology,AirwayResearchCenterNorth,GermanCenterforLungResearch,LungClinic,Grosshansdorf,Germany
Availableonline23January2023
Keywords:ESCAT,ESMOClinicalPracticeGuideline(CPG),ESMO-MCBS,oncogene-addictedmetastaticnon-small-cell
lung cancer (mNSCLC), treatment, targeted therapy
INCIDENCE AND EPIDEMIOLOGY therapy.ThefrequencyofoncogenicdriversinNSCLCaswell
as general discussion of testing strategy and methodology,
Details on incidence and epidemiology are covered in the
including the use of liquid biopsies, can be found in the
Supplementary Material Section 1, available at

4. (Therapy, score 3) logy,AirwayResearchCenterNorth,GermanCenterforLungResearch,LungClinic,Grosshansdorf,Germany
Availableonline23January2023
Keywords:ESCAT,ESMOClinicalPracticeGuideline(CPG),ESMO-MCBS,oncogene-addictedmetastaticnon-small-cell
lung cancer (mNSCLC), treatment, targeted therapy
INCIDENCE AND EPIDEMIOLOGY therapy.ThefrequencyofoncogenicdriversinNSCLCaswell
as general discussion of testing strategy and methodology,
Details on incidence and epidemiology are covered in the
including the use of liquid biopsies, can be found in the
Supplementary Material Section 1, available at
Supplementary Material Section 3,

5. (Treatment, score 2) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical
Practice Guideline for diagnosis, treatment and follow-up
L. E. Hendriks1, K. M. Kerr2, J. Menis3,T. S. Mok4, U. Nestle5,6, A. Passaro7, S. Peters8, D. Planchard9, E. F. Smit10,11,
B. J. Solomon12, G.Veronesi13,14 & M. Reck15, on behalf of the ESMO Guidelines Committee(cid:1)
1DepartmentofPulmonology,GROWSchoolforOncologyandReproduction,Maas

6. (Treatment, score 2) E-mail:clinicalguidelines@esmo.org(ESMOGuidelinesCommittee). largegroupofexon20insertionsmostlyresistanttocurrent
5Note:ApprovedbytheESMOGuidelinesCommittee:February2002,last EGFRTKIsbutsensitivetosomeemergingagents(discussed
updateDecember2022.Thispublicationsupersedesthepreviouslypublished in the treatment paragraph including EGFR exon 20 in-
versiondAnnOncol2018;29(Suppl4):iv192-iv237.
sertions). Other mutations, including in exon 18, variably
0923-7534/Â©2023EuropeanSociety forMedicalOncology. Published by
sensitise, while some mutations confer resistance and may
ElsevierLtd.Allrightsreserved.
Volum

7. (Therapy, score 2) e mutations confer resistance and may
ElsevierLtd.Allrightsreserved.
Volume34 - Issue 4 - 2023  339
drive disease relapse. Complete sequencing ofexons 18-21 Resistanceto kinase inhibitorsis almostinevitableandis
by next-generation sequencing (NGS) is strongly recom- variably due to the emergence of therapy-resistanttumour
mended,toidentifyallpossiblesensitisingmutations.Some cell clones with target gene alteration, increased bypass
allele-specific EGFR sequencing solutions do not provide pathwaysignallingand/orphenotypictransformation(small-
complete coverage. EGFR FISH or immunohistochemistry cell,

## Comparator

## Outcome

1. (Result, score 2) the
Alterations in structure and/or expression of the MET 2021 World Health Organization classification of lung
genedriveoncogenesisinNSCLC.3,5HighMETproteinlevels tumours [IV, A].
may be detected by IHC. Increased MET signalling may (cid:3) Specific subtyping of all NSCLCs is necessary for thera-
result from high gene copy number (GCN), either due to peutic decision making and should be carried out wher-
polysomyortruegeneamplification.Detectionisreliableby ever possible. IHC stains should be used to reduce the
in situ hybridisation (ISH) techniques, but NGS or compar- NSCLC-not otherwise specifie

